

Equity Research

December 30, 2014

Morning Call

Today's Research Highlights

Digital Media

FULL NOTE

CES 2015 Preview: Likely Stock Triggers and Technology Trends

The Cowen Insight

We see NEON and SYNA as most likely in our universe to enjoy a CES bounce on design win news. DTSI (Headphone:X) and OLED (new displays) are wild cards as potential triggers may be already priced in. Other factors matter more for CTRL, HEAR, ROVI, SSYS, and VOXX. Tech trends we'll be looking for include: connected cars & homes, quantum dot TVs, UHD & flexible OLEDs, and wearable devices.

Robert W. Stone

617 946 3932 rob.stone@cowen.com

Ultragenyx

FULL NOTE

Price: \$44.06 (12/26/2014)

Price Target: NA

OUTPERFORM (1) Key Data

Symbol NASDAQ: RARE Market Cap (MM) \$1,405.5

Eric Schmidt. Ph.D.

646.562.1345 eric.schmidt@cowen.com

KRN23: More Than Just XLH

The Cowen Insight

Ultragenyx recently initiated a trial of KRN23 (anti-FGF23 mAb) in ENS and TIO. This is the first expansion of KRN23 beyond the XLH market (sales modeled as >\$1.4B WW). We believe ENS, TIO and other disorders of FGF23 overproduction (e.g. ADHR, ARHR) could support \$650MM+ in upside to KRN23 sales estimates. With multiple data readouts in 2015, Ultragenyx remains a top pick.

Price: \$43.42 (12/26/2014) Price Target: \$53.00 (Prior \$42.00)

OUTPERFORM (1) Key Data

Symbol NASDAQ: VA Market Cap (MM) \$1,864.4

Helane Becker

646 562 1399

helane.becker@cowen.com

www.cowen.com

Virgin America

FULL NOTE

Raising Price Target

The Cowen Insight

We are raising our price target on the common shares of Virgin America to \$53 which is 11x 2015 EPS of \$4.80E per share. The shares hit our original price target of \$42, and the company hasn't yet realized any of the benefits we expect for 2015.

Earnings Per Share \$	2014E	2015E	2016E
Cowen	\$9.97	\$4.80	\$4.90
Consensus	-	4.16	3.39

Please see addendum of this report for important disclosures.

Other Research Today

CSC: Announces Potential S.E.C. Settlement

Computer Sciences

The Cowen Insight

FULL NOTE

Price: \$63.98 (12/29/2014) **Price Target: \$75.00**

OUTPERFORM (1) Key Data

Symbol NYSE: CSC Market Cap (MM) \$8,988.6

Moshe Katri 646.562.1327

2

moshe.katri@cowen.com

We believe potential S.E.C. settlement (restatement FY09-12 results; penalty) removes an important overhang, while focus remains on ongoing revenue/EPS growth recovery.

Upcoming Conferences

36th Annual Aerospace/Defense Conference & Transport One-on-One Forum

Wednesday, February 4 and Thursday, February 5, 2015

The Palace Hotel, New York, New York

35th Annual Health Care Conference

Monday, March 2 through Wednesday, March 4, 2015

The Boston Marriott Copley Place, Boston, Massachusetts

43rd Annual Technology, Media & Telecom Conference

Wednesday, May 27 and Thursday, May 28, 2015

The Palace Hotel, New York, New York

Morning Call

December 30, 2014

Points Of Contact

Product Management

Drew Payne

Product Manager 646.562.1579

Matt Petricone

617.946.3879

Alexander Katzman

646.562.1597

Trading Desk

New York

646.562.1500


Boston

617.946.3890

www.cowen.com 3

Morning Call

December 30, 2014



Analyst Certification

Each author of this research report hereby certifies that (i) the views expressed in the research report accurately reflect his or her personal views about any and all of the subject securities or issuers, and (ii) no part of his or her compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views expressed in this report.

Important Disclosures

This report constitutes a compendium report (covers six or more subject companies). As such, Cowen and Company, LLC chooses to provide specific disclosures for the companies mentioned by reference. To access current disclosures for the all companies in this report, clients should refer to https://cowen.bluematrix.com/sellside/Disclosures.action or contact your Cowen and Company, LLC representative for additional information.

Cowen and Company, LLC compensates research analysts for activities and services intended to benefit the firm's investor clients. Individual compensation determinations for research analysts, including the author(s) of this report, are based on a variety of factors, including the overall profitability of the firm and the total revenue derived from all sources, including revenues from investment banking. Cowen and Company, LLC does not compensate research analysts based on specific investment banking transactions.

Disclaimer

This research is for our clients only. Our research is disseminated primarily electronically and, in some cases, in printed form. Research distributed electronically is available simultaneously to all Cowen and Company, LLC clients. All published research can be obtained on the Firm's client website, https://cowenlibrary.bluematrix.com/client/library.jsp.

Further information on any of the above securities may be obtained from our offices. This report is published solely for information purposes, and is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. Other than disclosures relating to Cowen and Company, LLC, the information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete statement or summary of the available data. Any opinions expressed herein are statements of our judgment on this date and are subject to change without notice.

For important disclosures regarding the companies that are the subject of this research report, please contact Compliance Department, Cowen and Company, LLC, 599 Lexington Avenue, 20th Floor, New York, NY 10022. In addition, the same important disclosures, with the exception of the valuation methods and risks, are available on the Firm's disclosure website at https://cowen.bluematrix.com/sellside/Disclosures.action.

Price Targets: Cowen and Company, LLC assigns price targets on all covered companies unless noted otherwise. The price target for an issuer's stock represents the value that the analyst reasonably expects the stock to reach over a performance period of twelve months. The price targets in this report should be considered in the context of all prior published Cowen and Company, LLC research reports (including the disclosures in any such report or on the Firm's disclosure website), which may or may not include price targets, as well as developments relating to the issuer, its industry and the financial markets. For price target valuation methodology and risks associated with the achievement of any given price target, please see the analyst's research report publishing such targets.

Notice to UK Investors: This publication is produced by Cowen and Company, LLC which is regulated in the United States by FINRA. It is to be communicated only to persons of a kind described in Articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. It must not be further transmitted to any other person without our consent.

Copyright, User Agreement and other general information related to this report

© 2014 Cowen and Company, LLC. Member NYSE, FINRA and SIPC. All rights reserved. This research report is prepared for the exclusive use of Cowen clients and may not be reproduced, displayed, modified, distributed, transmitted or disclosed, in whole or in part, or in any form or manner, to others outside your organization without the express prior written consent of Cowen. Cowen research reports are distributed simultaneously to all clients eligible to receive such research reports. Any unauthorized use or disclosure is prohibited. Receipt and/or review of this research constitutes your agreement not to reproduce, display, modify, distribute, transmit, or disclose to others outside your organization the contents, opinions, conclusion, or information contained in this report (including any investment recommendations, estimates or price targets). All Cowen trademarks displayed in this report are owned by Cowen and may not be used without its prior written consent.

Cowen and Company, LLC. New York (646) 562-1000 Boston (617) 946-3700 San Francisco (415) 646-7200 Chicago (312) 577-2240 Cleveland (440) 331-3531 Atlanta (866) 544-7009 London (affiliate) 44-207-071-7500

COWEN AND COMPANY RATING DEFINITIONS

Cowen and Company Rating System effective May 25, 2013

Outperform (1): The stock is expected to achieve a total positive return of at least 15% over the next 12 months

Market Perform (2): The stock is expected to have a total return that falls between the parameters of an Outperform and Underperform over the next 12 months

Underperform (3): Stock is expected to achieve a total negative return of at least 10% over the next 12 months

Assumption: The expected total return calculation includes anticipated dividend yield

Cowen and Company Rating System until May 25, 2013

Outperform (1): Stock expected to outperform the S&P 500

Neutral (2): Stock expected to perform in line with the S&P 500

Underperform (3): Stock expected to underperform the S&P 500

Assumptions: Time horizon is 12 months; S&P 500 is flat over forecast period

Cowen Securities, formerly known as Dahlman Rose & Company, Rating System until May 25, 2013

Buy – The fundamentals/valuations of the subject company are improving and the investment return is expected to be 5 to 15 percentage points higher than the general market return

Sell – The fundamentals/valuations of the subject company are deteriorating and the investment return is expected to be 5 to 15 percentage points lower than the general market return

Hold – The fundamentals/valuations of the subject company are neither improving nor deteriorating and the investment return is expected to be in line with the general market return

Morning Call

December 30, 2014

Cowen And Company Rating Definitions

Distribution of Ratings/Investment Banking Services (IB) as of 09/30/14

Rating	Count	Ratings Distribution	Count	IB Services/Past 12 Months
Buy (a)	440	59.95%	105	23.86%
Hold (b)	278	37.87%	10	3.60%
Sell (c)	16	2.18%	0	0.00%

(a) Corresponds to "Outperform" rated stocks as defined in Cowen and Company, LLC's rating definitions. (b) Corresponds to "Market Perform" as defined in Cowen and Company, LLC's ratings definitions. (c) Corresponds to "Underperform" as defined in Cowen and Company, LLC's ratings definitions.

Note: "Buy", "Hold" and "Sell" are not terms that Cowen and Company, LLC uses in its ratings system and should not be construed as investment options. Rather, these ratings terms are used illustratively to comply with FINRA and NYSE regulations.

www.cowen.com

Equity Research



Points Of Contact

Reaching Cowen

Main U.S. Locations

New York

599 Lexington Avenue New York, NY 10022 646.562.1000 800.221.5616

Atlanta

3399 Peachtree Road NE Suite 417

Atlanta, GA 30326 866.544.7009

Boston

Two International Place Boston, MA 02110 617.946.3700 800.343.7068

Chicago

181 West Madison Street Suite 1925 Chicago, IL 60602 312.577.2240

Cleveland

20006 Detroit Road Suite 100 Rocky River, OH 44116 440.331.3531

San Francisco

555 California Street, 5th Floor San Francisco, CA 94104 415.646.7200 800.858.9316

International Locations

Cowen International Limited

London

1 Snowden Street - 11th Floor London EC2A 2DQ **United Kingdom** 44.20.7071.7500

Cowen and Company (Asia)

Limited

Hong Kong

Suite 1401 Henley Building No. 5 Queens Road Central Central, Hong Kong 852 3752 2333





